The Parkinson disease is due to the destruction of certain neurons located in the substantia nigra of the brain. Involved in the control of movement, these neurons produce a neurotransmitter called dopamine. When it is lacking, well-known symptoms appear: slowness of movements, muscle stiffness, tremors at rest or motor disturbances (difficulty in walking, loss of balance) … Current drugs can compensate for this. dopamine deficiency, but over time their effect tends to diminish. Today, researchers are therefore trying to act directly on the origin of the disease by preventing the destruction of neurons.
First track explored: the iron. Essential to life, it allows good oxygenation of cells. But poorly distributed or in excess in the body, it can also damage them. This is precisely the case in Parkinson’s disease, where iron overload is observed in the substantia nigra.
A vaccine to be tested from the start of the school year
To reduce this excess without causing anemia, a molecule has been developed, deferiprone. ” A big clinical study led by the Lille University Hospital is currently underway in 24 European centers. It will include 338 patients at an early stage of the disease ”, specifies Professor Jean-Philippe Azulay.
Iron is not the only molecule whose excess is involved in the Parkinson disease. Alpha-synuclein, a protein normally present in the brain, becomes insoluble in patients and forms aggregates leading to destruction of neurons. Aggravating factor : these toxic elements spread from one neuron to another, thus contributing to the gradual disappearance of nerve cells.
“One of the avenues explored by research consists in blocking the spread of this toxic form of alpha-synuclein by what is called immunotherapy,” indicates Professor Azulay. There are two ways you can do it. In the first case, a vaccine is developed which will trigger the action of immune cells against alpha-synuclein. In the second, the patient is injected with antibodies directed against this protein, developed in the laboratory. This latter approach will be tested in a study which will begin in September. “
An antidiabetic under study
According to several studies, a drug indicated for the treatment of diabetes, the’exenatide, appears to have a neuroprotective effect, but more research is needed to be sure. “For the moment, it is difficult to know if these leads will really lead to new treatments”, estimates Professor Azulay. But the hope is real: there will be one that will be the right one!
Read also:
An anti-diabetic for Parkinson’s disease?
Parkinson’s disease: what if we replaced damaged brain cells?
Parkinson’s disease starts in the intestine
